Restless Legs Syndrome Risk Higher in People with Multiple Sclerosis, Study Finds

Why It Matters

Higher RLS rates add to the symptom burden of MS and can worsen sleep quality, prompting clinicians to integrate neurologic and sleep assessments.

Key Takeaways

• MS patients show 15% RLS prevalence.
• RLS risk doubles compared to non‑MS controls.
• Pyramidal symptoms increase RLS odds fivefold.
• Spinal cord lesions reduce RLS likelihood by 60%.

Pulse Analysis

Restless legs syndrome (RLS) has long been recognized as a disruptive sleep disorder, but its intersection with multiple sclerosis (MS) has received limited attention. The recent Spanish cohort, encompassing 440 treated MS patients and 241 age‑ and sex‑matched controls, reveals a confirmed RLS prevalence of 15.2% in the MS group—roughly twice the 7.9% observed in the general population. This elevated rate underscores a hidden layer of morbidity that can exacerbate fatigue, a hallmark symptom of MS, and highlights the need for neurologists to look beyond classic disease markers.

The study’s two‑step diagnostic protocol—initial questionnaire followed by specialist confirmation—cut false‑positive rates to 22%, illustrating the importance of rigorous assessment. Notably, patients exhibiting pyramidal tract dysfunction, such as muscle weakness or spasticity, faced a four‑ to five‑fold increase in RLS odds, while those with spinal cord lesions showed a 60% risk reduction. A positive family history further amplified susceptibility, suggesting a genetic component that may interact with MS‑related neurodegeneration. These findings align with emerging evidence that motor pathway damage can trigger sensory‑motor dysregulation characteristic of RLS.

From a clinical standpoint, integrating routine RLS screening into MS care pathways could mitigate sleep disruption and improve overall quality of life. Simple tools like the four‑question RLS screener, paired with referral to sleep‑disorder specialists for confirmation, can be embedded in neurology visits, especially for patients reporting nocturnal leg discomfort or worsening fatigue. Early identification also opens therapeutic avenues—dopaminergic agents, iron supplementation, or physiotherapy—that may alleviate symptoms without compromising MS treatment. Future research should explore longitudinal outcomes of combined MS‑RLS management and investigate whether disease‑modifying therapies influence RLS prevalence.